CLS 005

Drug Profile

CLS 005

Alternative Names: CLS005

Latest Information Update: 10 Dec 2016

Price : $50

At a glance

  • Originator Cutanea Life Sciences
  • Class Skin disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Rosacea

Most Recent Events

  • 08 Dec 2016 Phase-III clinical trials in Rosacea (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top